I do not think Anavex will sell out until FDA submission...or even FDA approval. If approved in Europe, the political pressure on the FDA to do the same will become quite strong. A3-71 favorable results would also obviously add value. Do you think Anavex could sell only the rights to Blarcamesine, and keep A3-71? If so, then they could issue a special dividend, and remain a smaller sized development company, but with enough cash to fund multiple trials simultaneously.